Mclean Hospital

160 total trials 137 currently recruiting 21 completed

Trial Pipeline

RECRUITING NA

Stress Dynamics and Familial Risk for Depression in Female Adolescents

NCT06816329

RECRUITING Phase 1

Pharmacologic Augmentation of TMS for Depression With D-serine

NCT06876129

RECRUITING Phase 2

Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

NCT05232032

RECRUITING NA

Mechanisms of Exposure Therapy for OCD

NCT06173752

RECRUITING NA

Cerebellar Modulation of Cognition in Psychosis

NCT06107764

RECRUITING Phase 2

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965

RECRUITING NA

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

NCT06221852

RECRUITING Phase 2

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

NCT06477406

RECRUITING NA

Enhanced Coordinated Specialty Care for Early Psychosis

NCT06071858

RECRUITING Phase 2

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

NCT05837104

RECRUITING

Following Outcomes Remotely Within Addiction Recovery Domains

NCT06001437

RECRUITING NA

Role of Parent Interpretation Bias in the Transmission of Anxiety to Children

NCT05665491

RECRUITING Phase 2

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

NCT05457465

RECRUITING NA

Individually Targeted Neuromodulation for Contamination-based OCD

NCT05048251

RECRUITING

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

NCT05245903

RECRUITING NA

Interpretation Bias as a Mechanism of Treatment Response in OCD

NCT05224414

RECRUITING Early Phase 1

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517

RECRUITING

Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

NCT05630963

RECRUITING NA

Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents

NCT04697966

RECRUITING NA

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

NCT05343598

RECRUITING NA

Neural Correlates of Stress and Perceived Control in Adolescent Depression

NCT04788524

RECRUITING

Early Life Stress and Depression: Molecular and Functional Imaging

NCT04713722

RECRUITING Early Phase 1

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT04075435

ACTIVE NOT RECRUITING

Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)

NCT04325529

ACTIVE NOT RECRUITING NA

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT03484494

COMPLETED

Online Emotional Response to Completing a Childhood Maltreatment Self-report Scale

NCT06152549

COMPLETED Phase 4

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

NCT05537584

COMPLETED NA

Families With Substance Use and Psychosis: A Pilot Study

NCT04284813

COMPLETED

Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains

NCT02855229

COMPLETED

Feasibility of Collateral Information Review and Its Impact on Clinical Decision-Making

NCT04635748

COMPLETED NA

Cognitive Bias Modification for OCD

NCT03799419

COMPLETED Phase 1

Effect of Nicotine on Brain Reward Pathways

NCT02346539

COMPLETED NA

Study of Treatment for Opioid Dependence and Anxiety Disorders

NCT02252068

COMPLETED NA

Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment

NCT02305537

COMPLETED NA

Neural Mechanisms Underlying Nicotine and Alcohol Combinations

NCT02049268

COMPLETED

Brain Mechanisms of Emotion and Motivation: A Mind-Body Study

NCT01850472

COMPLETED

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

NCT01688765

COMPLETED

Depression and Dopamine Transporter Function Study Using C-11 Altropane

NCT01701141

COMPLETED

Dopamine Neurotransmission in Major Depression

NCT01659814

COMPLETED Phase 4

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979

COMPLETED NA

A Trial of SAMe for Treatment-Resistant Bipolar Depression

NCT00762268

COMPLETED NA

Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device

NCT00578383

COMPLETED Phase 1

Transdermal Electroacupuncture for Opioid Detoxification

NCT00742170

COMPLETED Phase 2

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

NCT00431184

COMPLETED NA

Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels

NCT01588561

COMPLETED Phase 3

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

NCT00125957

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 37
Phase 3 1
Phase 4 2

What the Pipeline for Mclean Hospital Shows

According to the ClinicalTrials.gov registry, Mclean Hospital is linked to 160 US clinical trials across every stage of research activity. Of those, 137 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 21 are already marked complete, representing roughly 13% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Mclean Hospital reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 42 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Mclean Hospital is Major Depressive Disorder with 9 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial